Streetwise Life Sciences Tools & Diagnostics Articles


Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >

Exciting Biotech Stock Now Breaking Out of Large Base

Contributed Opinion
  ()
Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy. read more >

Fund Manager Names Three Small-Caps with Strong Growth Profiles

  ()
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects. read more >

Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?

  ()
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma. read more >

Company Takes Aim at Approval of Colorectal Cancer Screening Test in EU

  ()
Two analysts take note as this biotech prepares to release data on its colorectal cancer screening product. read more >
Showing Results: 1 to 5 of 5

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We continue to view DRRX as undervalued and reiterate our Buy rating." ❭
– Francois Brisebois, Laidlaw & Company
"We are initiating coverage on PMN." ❭
– John Vandermosten, Zacks Small-Cap Research
"SPR's acquisition in the pipeline creates water-soluble cannabis." ❭
– Chris Parry, Equity Guru